United Therapeutics Corp. (UTC) and Liquidia Technologies Inc. have been battling for close to a decade over their respective inhaled formulations ...

Transplanting gut microbes from healthy rats into a rat model of PAH led to a reduction in disease severity, suggesting a ...

In this randomized controlled trial of patients with pulmonary arterial hypertension (PAH) and high risk of mortality, ...

A novel screening approach developed by physicians at the Lewis Katz School of Medicine at Temple University shows ...

Research from Anjali Vaidya, MD, FACC, FASE, FACP, Temple University Hospital, reveals critical care gaps for patients with ...

Yutrepia is an inhaled dry powder formulation of treprostinil approved in the U.S. to improve exercise capacity in PAH and PH ...

A Hundred Experts Urge Strengthening Early Diagnosis of Pulmonary Hypertension in Latin America ...

Pulmonary arterial hypertension (PAH) is an incurable disease initiated ... which provides a novel mechanistic view into BMPR2 deficiency and may offer new targets for PAH treatment. This work was ...

Like other inhaled prostaglandins, YUTREPIA may cause acute bronchospasm. Patients with asthma or chronic obstructive pulmonary disease (COPD), or other bronchial hyperreactivity, are at increased ...

Background Pulmonary hypertension (PH) is a progressive cardiopulmonary condition associated with increased morbidity and ...

Keros will be down to 85 full-time employees after the layoffs and expects to generate annualized savings of $17 million.

Among patients with pulmonary arterial hypertension treated with selexipag, the 10-year survival rate was 60%, according to ...